Guidelines
Now CAMZYOS® (mavacamten) is recommended in the 2023 ESC new guidelines for the management of cardiomyopathies. The first and so far only cardiac myosin inhibitor for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.
IIa
A
The selective ATPase cardiac myosin inhibitor (mavacamten) titrated to the maximum tolerated dose with echocardiographic monitoring of LEF, should be considered in addition to a beta-blocker (or if this is not possible, with verapamil or diltiazem) to improve symptoms in adult patients with quiescent or provoked LVOTO.
IIa
B
The selective ATPase cardiac myosin inhibitor (mavacamten) titrated to the maximum tolerated dose with echocardiographic monitoring of LVEF, should be considered as monotherapy in symptomatic adult patients with resting or provoked LVOTO (exercise or Valsava maneuver) who are intolerant or have contraindications to beta-blockers, verapamil / diltiazem or disopyramide.
References:
1. CAMZYOS®, Product Information current edition
12. 2023 ESC Guidelines for the management of cardiomyopathies